
via Indiana University School of Medicine
For people with diabetes who are insulin dependent, glycemic control is a full-time job. But what if their medication could do the work for them—an insulin whose activity in the bloodstream responds to the blood glucose levels and adjusts accordingly?
An invention from Indiana University School of Medicine Distinguished Professor Michael A. Weiss, MD, PhD, could lead to just that.
In a breakthrough study published in the peer-reviewed journal PNAS, Weiss and his team describe the use of a synthetic “switch” that can be opened or closed using a simple sugar sensor. The study was in part collaborative with Thermalin, Inc., a small biotech company that Weiss began in 2008.
Their concept exploits a natural mechanism, designated the “protective hinge,” that is built into vertebrate insulins. The protective hinge is a natural structural feature that evolved more than half a billion years ago to keep the hormone stable in its closed state but foldable and functional in its open state.
“The reason a glucose-responsive insulin is important is that the biggest barrier to the effective use of insulin, especially in Type 1 diabetes, is the fear of the consequences of blood sugar going too low,” said Weiss, who is also the Chair of the Department of Biochemistry and Molecular Biology.
Immediate consequences of severely low blood sugar (hypoglycemia) can include delirium, convulsions or loss of consciousness, and repeated episodes of severe hypoglycemia can cause cognitive decline. On the other hand, chronic high blood sugar (hyperglycemia) can lead to blindness, stroke or amputation. Staying in the desired blood glucose range is a delicate balance that insulin-dependent diabetics face every day.
But Weiss said that he envisions a future when people do not have to choose to risk their long-term health to protect themselves from the immediate dangers of severe hypoglycemia.
“The promise of this kind of ‘smart’ insulin is that it would transform diabetes care, so people wouldn’t have to worry anymore,” said Weiss. “With our invention, we envision that when the blood sugar goes low, the hinge would close. But there will be much work to do to translate our proof of principle to an FDA-approved product.”
In the 100 years since the discovery of insulin, its use as a treatment for diabetes has gone through many significant changes. C. Ronald Kahn, MD, chief academic officer at the Joslin Diabetes Center at Harvard Medical School, said that glucose-responsive insulin could be the next.
“In the recent study from the Weiss laboratory appearing in PNAS, we see an example of the next exciting phase of insulin development, namely development of an insulin analogue which through chemical modification can sense the level of sugar present in the blood,” said Kahn. “While the current analogue has been designed to sense fructose, it seems likely that this same approach can be used to develop analogues to sense glucose. Whether these can be sensitive enough to be modulated by changes within the physiological range remains to be determined, but if so, this would be an important new tool in the management of diabetes.”
Other types of glucose-responsive insulins are being developed elsewhere. What makes Weiss’ invention unique is its simplicity. The synthetic hinge exploits naturally occurring processes and introduces fewer external or artificial elements compared to other approaches.
While their study uses fructose as model (representative of a monosaccharide like glucose), it proves that Weiss’ synthetic hinge concept works. His team is already working on glucose-responsive insulin candidates that open and close at the desired high and low glucose thresholds, which are respectively 70 to 180 milligrams per deciliter. By replacing the fructose sensor with glucose sensors, a revolutionary insulin therapy may be closer than we think.
Original Article: Synthetic hinge could hold key to revolutionary “smart” insulin therapy
More from: Indiana University School of Medicine | Indiana University | Case Western Reserve University | University of Melbourne
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Glucose-responsive insulin
- Eating certain foods may do the same thing as Ozempic and related drugs — without the side-effects
Ozempic (and the similar drug Wegovy) has had more than its fair share of headlines and controversies. A global supply shortage, tweets about using it from Elon Musk, approval for adolescent weight ...
- Ozempic helps weight loss by making you feel full. But certain foods can do the same thing – without the side-effects
Our body needs insulin to move the glucose or blood sugar we get from food inside cells, so we can use it as energy.Semaglutide works by mimicking the role of a natural hormone, called GLP-1 glucagon ...
- Open-Source Insulin: Biohackers Aiming For Distributed Production
Specialized cells, called beta cells, sense the level of glucose in the blood, which typically spikes after eating a meal, and secrete insulin into the bloodstream in response. Insulin quickly ...
- Losing key type of pancreatic cell may contribute to diabetes
Multiple types of beta cells produce insulin in the pancreas, helping to balance blood sugar levels. Losing a particularly productive type of beta cell may contribute to the development of diabetes, ...
- Amiclear Reviews - Is It Nature’s Secret for Blood Sugar Support or Cheap Supplement?
Various factors, including obesity, overweight, genetics, unhealthy lifestyle, and more, can cause harmful blood sugar levels. If your blood sugar is not regulated, it poses a risk of diabetes.
Go deeper with Google Headlines on:
Glucose-responsive insulin
[google_news title=”” keyword=”glucose-responsive insulin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Smart insulin
- Consuming low-insulin-stimulating bread significantly reduces body weight
In a recent study published in the journal Nutrients, researchers discuss the results of a randomized controlled trial (RCT) evaluating the impact of low-insulin-stimulating bread on weight ...
- Insulin Pens Market is projected to be valued at US$ 4.9 billion by 2033 is exhibiting a 4.7% CAGR
The global Insulin Pens Market is expected to grow at a CAGR of 6.5% during the period 2023-2033. The market is holding a valuation of US$ 35 billion as of 2023. The market is projected to be valued ...
- My son needs insulin to survive. Plans to lower drug costs are welcome, but not enough.
Novo Nordisk and Sanofi announced last week that they will lower prices on some of their insulin products by up to 78% effective January 2024. That follows Eli Lilly’s recent announcement ...
- Smart Insulin Pens Market 2023 Industry Breakdown for Major Key Player, Growth Factors, Demand Forecast to 2031
Report Ocean's brand-new analysis from researchers on the Smart Insulin Pens Market details market size, demand, growth trends, and future projections. In order to be able to fulfill rising demand, ...
- Open-Source Insulin: Biohackers Aiming For Distributed Production
When you’ve got a diabetic in your life, there are few moments in any day that are free from thoughts about insulin. Insulin is literally the first coherent thought I have every morning ...
Go deeper with Google Headlines on:
Smart insulin
[google_news title=”” keyword=”smart insulin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]